You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content.
If you’re over 50 years of age and have had chickenpox, the virus that causes shingles may be inside your body and can reactivate at any time. Around 1 in every 3 people will get shingles in their lifetime. No matter how healthy you feel, your immune system declines as you age, and that puts you at an increased risk for shingles.1,2,7,10-12,23
Shingles itself is not contagious. It can’t spread from one person to another. However, the varicella zoster virus, the same virus that causes chickepox, is contagious. People who never had chickenpox can get infected with varicella zoster virus from someone who has shingles. Moreover, a person can spread the virus when the shingles rash is in the blister phase. It is important to keep the shingles rash covered until the blisters form a crust.23
Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 mcg (AS01B adjuvanted vaccine)) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older and for adults 18 years of age or older who are at increased risk of herpes zoster. SHINGRIX, a prescription medicine, is funded for people aged 65 years. From 1 July 2024, SHINGRIX is also funded for certain individuals 18 years and over at higher risk of shingles. See full funding criteria at pharmac.govt.nz. Costs will apply if SHINGRIX is not funded. A single 0.5mL dose contains 50 mcg of gE antigen, adjuvanted with AS01B (composed of the plant extract Quillaja saponaria saponin (QS-21) (50 mcg) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 mcg) plus excipients). SHINGRIX should not be administered if you are hypersensitive to any component of this vaccine. SHINGRIX has risks and benefits – ask your doctor if SHINGRIX is right for you. Use strictly as directed. Normal doctor’s charges apply. Side effects: Adults ≥50 years: pain, redness and swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and gastrointestinal symptoms. Adults at increased risk of shingles between the ages of 18 to 49 years are more likely to experience side effects such as pain at the injection site, fatigue, muscle pain, headache, shivering and fever compared to those aged ≥50 years. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP21925 - PM-NZ-SGX-WCNT-240002 Date of Approval: 11 2024 Date of Expiry: 11 2026
Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional’s advice.
This website is funded and developed by GSK. This site is intended for NZ residents only.
©2024 GSK group of companies or its licensor. Last updated: November 2024.